Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s claim regarding duration (months), incomplete dissolution, and recurrence (up to 50% within 5 years) is directly supported by the provided FDA label excerpts (SPECIAL NOTE and Clinical Results). No contradictions or unsafe additions were identified within the scope of the stated claim.
Category Scores
Accurate Statements
Ursodiol gallbladder stone dissolution requires months of therapy; complete dissolution does not occur in all patients; and stone recurrence within 5 years has been observed in up to 50% of patients who do dissolve.
SUPPORTED: SPECIAL NOTE (“requires months of therapy”; “Complete dissolution does not occur in all patients”; “recurrence of stones within 5 years…up to 50% of patients who do dissolve”), and Clinical Results (“Stone recurrence has been observed in up to 50% of patients within 5 years of complete stone dissolution”).
Unsupported Statements
Contradictions
Important Omissions
The AI did not include the label’s additional context that recurrence estimates are tied to complete dissolution and that serial ultrasonographic examinations should be obtained to monitor for recurrence.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content is descriptive of expected dissolution/recurrence patterns and is directly supported by the provided label excerpts; no dosing, contraindication, or safety-management instructions were added beyond label-supported statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of monitoring/clinical-management context that is present in the label (e.g., serial ultrasonography to monitor recurrence) while the main claim remains supported.
Suggested Improvement
When describing recurrence/dissolution expectations, also include the label’s recommendation to obtain serial ultrasonographic examinations to monitor for recurrence (and the condition that radiolucency should be established before another course is instituted).